Pfizer Pharmaceuticals now owns twenty two years of research that led to the development of new technology to treat patients. This new and improved gene therapy will target the myelin making cells in the brains of children and young adults and enable doctors to deliver a customized medicine for Canavan disease. This technology was largely funded by families of affected children, charitable organizations, and the NIH.
Pfizer has nearly unlimited resources available to move this science to a clinical trial and ultimately develop a one-time treatment to potentially cure Canavan disease. This type of funding has never been possible for Canavan disease research before.
We are excited about the possibilities that massive financial support can bring with it to help patients. But Pfizer's interest in Canavan disease and their initial investment to acquire our technology is only the first step. Now they need to hear from the patients and their families. We need to ensure that this technology doesn't sit on a shelf while our children continue to die.
It was this sense of urgency that first united our families and organizations to help get Canavan as far as it has, but please don't let it end here. We have come too far and fought too hard to stop now. Pfizer now holds the power to decide the fate of years of research and hard work by determining the order, and even what diseases they decide to set on course for a clinical trial.
They will listen to patients and the people who care about them. Canavan is fatal and progressive, time is essential and Canavan disease must be made a priority. We are on the radar but we need to become a top priority! Our children cannot speak for themselves, please be the voice of our children and ask Pfizer to make Canavan a priority for treatment.
Dear Ian C. Read,
I am writing to you on behalf of the children and families affected by Canavan disease. The technology to save our children has been acquired by Pfizer through the purchase of Bamboo Therapeutics. We are now relying on you to move ahead quickly and put Canavan on a direct path to a clinical trial. Canavan disease must become a priority because it is progressive and fatal.
I realize that this is primarily about money and profit. Insurance companies will continue to spend millions of dollars per child keeping our profoundly disabled, medically fragile children alive for years and possibly decades until you offer them a cure.
There are also secondary costs associated with Canavan disease. Caregivers and parents are much more likely to require ongoing medical care for chronic pain and injury due to the physical demands of taking care of disabled children and young adults. A one-time treatment is a much better and far less costly alternative for insurance companies.
Other opportunities for profit include your ability to use the perfected technology and treat millions of people suffering from more common related diseases such as ALS, Alzheimer's and Parkinson's. You will also be granted huge tax incentives if you advance this technology and help patients living with Canavan and other rare diseases.
If you are concerned about helping sick people and interested in developing drugs to improve their lives then please help these amazing children, they are a gift to the families who love and cherish them.
Thank you!
Sincerely,
Ilyce Randell
Patient Advocacy
Canavan Research Illinois
ao assinar, você aceita o termos de serviço da Care2 Você pode gerenciar suas assinaturas de e-mail a qualquer momento.
Está tendo algum problema?? Avise-nos.